258 related articles for article (PubMed ID: 8459317)
1. Photosensitizing properties of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors.
Spikes JD; Bommer JC
J Photochem Photobiol B; 1993 Feb; 17(2):135-43. PubMed ID: 8459317
[TBL] [Abstract][Full Text] [Related]
2. Photobleaching of mono-L-aspartyl chlorin e6 (NPe6): a candidate sensitizer for the photodynamic therapy of tumors.
Spikes JD; Bommer JC
Photochem Photobiol; 1993 Sep; 58(3):346-50. PubMed ID: 8234467
[TBL] [Abstract][Full Text] [Related]
3. [Potential of photodynamic therapy with a second-generation sensitizer: mono-L-aspartyl chlorin e6].
Mori K; Ohta M; Sano A; Yoneya S; Sonoda M; Kaneda A; Sato Y
Nippon Ganka Gakkai Zasshi; 1997 Feb; 101(2):134-40. PubMed ID: 9124093
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy of intestinal tumors with mono-L-aspartyl chlorin e6 (NPe6): a basic study.
Kikuchi T; Asakura T; Aihara H; Shiraki M; Takagi S; Kinouchi Y; Aizawa K; Shimosegawa T
Anticancer Res; 2003; 23(6C):4897-900. PubMed ID: 14981942
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study.
Taber SW; Fingar VH; Coots CT; Wieman TJ
Clin Cancer Res; 1998 Nov; 4(11):2741-6. PubMed ID: 9829737
[TBL] [Abstract][Full Text] [Related]
6. Mono-L-aspartyl chlorin e6 (NPe6) and hematoporphyrin derivative (HpD) in photodynamic therapy administered to a human cholangiocarcinoma model.
Wong Kee Song LM; Wang KK; Zinsmeister AR
Cancer; 1998 Jan; 82(2):421-7. PubMed ID: 9445202
[TBL] [Abstract][Full Text] [Related]
7. Phase-resolved fluorescence study of mono-L-aspartyl chlorin E6.
Li L; Kodama K; Saito K; Aizawa K
J Photochem Photobiol B; 2002 May; 67(1):51-6. PubMed ID: 12007467
[TBL] [Abstract][Full Text] [Related]
8. Morphologic evaluation of the antitumor activity of photodynamic therapy (PDT) using mono-L-aspartyl chlorin e6 (NPe6) against uterine cervical carcinoma cell lines.
Nakamura H; Suzuki Y; Takeichi M; Saito T; Takayama M; Aizawa K
Int J Gynecol Cancer; 2002; 12(2):177-86. PubMed ID: 11975677
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
Chan AL; Juarez M; Allen R; Volz W; Albertson T
Photodermatol Photoimmunol Photomed; 2005 Apr; 21(2):72-8. PubMed ID: 15752124
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): implication of topical NPe6-photodynamic therapy.
Wong TW; Aizawa K; Sheyhedin I; Wushur C; Kato H
J Pharmacol Sci; 2003 Oct; 93(2):136-42. PubMed ID: 14578580
[TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor by photodynamic therapy with mono-L-aspartyl chlorin e6 (NPe6) in oral squamous cell carcinoma.
Nakagawa H; Matsumiya T; Sakaki H; Imaizumi T; Kubota K; Kusumi A; Kobayashi W; Kimura H
Oral Oncol; 2007 Jul; 43(6):544-50. PubMed ID: 17257889
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy of experimental choroidal neovascularization with a hydrophilic photosensitizer: mono-L-aspartyl chlorin e6.
Mori K; Yoneya S; Anzail K; Kabasawa S; Sodeyama T; Peyman GA; Moshfeghi DM
Retina; 2001; 21(5):499-508. PubMed ID: 11642380
[TBL] [Abstract][Full Text] [Related]
13. Endovascular photodynamic therapy using mono-L-aspartyl-chlorin e6 to inhibit Intimal hyperplasia in balloon-injured rabbit arteries.
Nagae T; Aizawa K; Uchimura N; Tani D; Abe M; Fujishima K; Wilson SE; Ishimaru S
Lasers Surg Med; 2001; 28(4):381-8. PubMed ID: 11344521
[TBL] [Abstract][Full Text] [Related]
14. Low-level light therapy potentiates NPe6-mediated photodynamic therapy in a human osteosarcoma cell line via increased ATP.
Tsai SR; Yin R; Huang YY; Sheu BC; Lee SC; Hamblin MR
Photodiagnosis Photodyn Ther; 2015 Mar; 12(1):123-30. PubMed ID: 25462575
[TBL] [Abstract][Full Text] [Related]
15. The effects of serum on cellular uptake and phototoxicity of mono-L-aspartyl chlorin e6 (NPe6) in vitro.
Sheyhedin I; Aizawa K; Araake M; Kumasaka H; Okunaka T; Kato H
Photochem Photobiol; 1998 Jul; 68(1):110-4. PubMed ID: 9679456
[TBL] [Abstract][Full Text] [Related]
16. Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor.
Webber J; Leeson B; Fromm D; Kessel D
J Photochem Photobiol B; 2005 Feb; 78(2):135-40. PubMed ID: 15664500
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy with a diode laser for implanted fibrosarcoma in mice employing mono-L-aspartyl chlorin E6.
Katsumi TA; Aizawa K; Kuroiwa Y; Saito K; Kurata Y; Ii Y; Okunaka T; Konaka C; Kato H
Photochem Photobiol; 1996 Oct; 64(4):671-5. PubMed ID: 8863472
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse.
Kobayashi W; Liu Q; Nakagawa H; Sakaki H; Teh B; Matsumiya T; Yoshida H; Imaizumi T; Satoh K; Kimura H
Oral Oncol; 2006 Jan; 42(1):46-50. PubMed ID: 16266818
[TBL] [Abstract][Full Text] [Related]
19. Mono-(L)-aspartylchlorin-e6.
Hargus JA; Fronczek FR; Vicente MG; Smith KM
Photochem Photobiol; 2007; 83(5):1006-15. PubMed ID: 17880493
[TBL] [Abstract][Full Text] [Related]
20. The challenging combination of intense fluorescence and high singlet oxygen quantum yield in photostable chlorins--a contribution to theranostics.
Silva EF; Schaberle FA; Monteiro CJ; Dąbrowski JM; Arnaut LG
Photochem Photobiol Sci; 2013 Jul; 12(7):1187-92. PubMed ID: 23584281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
